A valuable addition to medical science is the quantification
of a specific protein in a complicated sample. Immunoassays target a specific
molecule of interest and assess its concentration in a sample using highly
specific antibodies. As a result, immunoassay can be defined as a biochemical
method that uses a specific antibody to assess the concentration of a specific
antigen.
The first immunoassay approach that can determine Nano molar
and Pico molar hormone concentrations in biological fluids is radioimmunoassay.
The RIA approach is based on the competitive binding principle, which states
that a radioactive antigen competes with a non-radioactive antigen for the
attention of a specific antibody. The RIA technique is employed in a variety of
disease diagnosis applications, including early cancer detection and diagnosis,
as well as the diagnosis of other infectious diseases, including neurological
disorders.
RIA is one of the most important and established methods for
diagnosing endocrine diseases. RIA is utilised in the pharmaceutical industry
for drug testing. The market for radioimmunoassay techniques in cancer
diagnosis is predicted to increase at a substantial rate throughout the
forecast period, owing to advances in medical research and rising use of
radioimmunoassay techniques in cancer diagnosis.
The global
radioimmunoassay market is predicted to increase significantly over the
forecast period, owing to rising cancer and other infectious disease
prevalence. Over the forecast period, the increasing use of RIA procedures in
research institutions, contract research organisations, and the pharmaceutical
industry will also drive the overall expansion of the radioimmunoassay market.
Additionally, increased need for high throughput and automated procedures in
research centres and diagnostic labs to ensure patients' satisfaction with
error-free findings is one of the important factors driving the
radioimmunoassay market expansion throughout the projection period.
The high cost of the method, as well as constant
improvements in alternative immunoassay procedures such as ELISA, are limiting
the growth of the worldwide radioimmunoassay market.
Comments
Post a Comment